Search
for
Sort by
Research 121–150 of 398
- Alopecia Areata: Current Treatments and New Directions
- Treatment preferences of adults and adolescents with alopecia areata: A discrete choice experiment
- Harnessing the Biomimetic Effect of Macromolecular Crowding in the Cell-Derived Model of Clubfoot Fibrosis
- Angelica sinensis promotes cortical regeneration of the thymus in mice with acute thymic involution induced by short-term rapamycin treatment
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
- Risk of Safety Events in Vitiligo Patients: A Retrospective Real‐World Data Study in the US
- Case Report: Alopecia areata in an adolescent after COVID-19 infection
- Deciphering the Complex Immunopathogenesis of Alopecia Areata
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Treatment of Refractory Segmental Vitiligo and Alopecia Areata in a Child with Upadacitinib and NB-UVB: A Case Report
- Hair-Growth-Promoting Effects of the Fish Collagen Peptide in Human Dermal Papilla Cells and C57BL/6 Mice Modulating Wnt/β-Catenin and BMP Signaling Pathways
- Exosomes based advancements for application in medical aesthetics
- Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
- Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Ritlecitinib in severe alopecia areata: a profile of its use
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
- A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics
- Evidence Synthesis Gone Awry: The Perils of Aggregating Ineffective or Unsafe Doses in Alopecia Areata Reviews
- Significance of the S100A4 Protein in Psoriasis
- FOXN1 Deficiency: from the Discovery to Novel Therapeutic Approaches
- Fatal autoimmunity results from the conditional deletion of Snai2 and Snai3
- Case Report: Successful treatment of pediatric alopecia universalis with ritlecitinib after failure of baricitinib
- Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata
- Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA